President Biden’s new prescription drug pricing efforts seem part of reelection strategy intended to highlight an area, healthcare, where the public has long held more favorable views of Democrats. But the initiative itself includes an aggressive exploration of patent “march-in” rights that has been rejected by previous Democratic administrations – and even the Biden team itself.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?